Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …

Background Genetically driven variations in the level of cytochrome P450 (CYP) 2D6
metabolic activity have been shown to significantly affect the pharmacokinetic behaviour of …

This study examines the relationship between blood concentrations of venlafaxine and its
active metabolite, O-desmethyl venlafaxine (ODV), and genetic variants of the cytochrome …

Rationale Two biomarkers: concentration ratio of O-desmethylvenlafaxine/venlafaxine and
concentration sum of venlafaxine+ O-desmethylvenlafaxine were adopted to indicate …

Background Venlafaxine (VEN), a well accepted anti-depressant, is metabolized through the
cytochrome P 450 (CYP) 2D6 isozyme to form O-desmethyvenlafaxine (ODV). Due to the …

Objective: The cytochrome P 450 isozymes CYP2D6 and CYP2C19 exhibit genetic
polymorphism in human, including a marked interethnic difference. As the functional status …

Background The association between CYP2D6 metabolizer status and clinical outcomes of
venlafaxine was extensively investigated previously, but no widely accepted conclusion has …

Background Venlafaxine (VEN) is a commonly utilized medication for alleviating depression
and anxiety disorders. The presence of genetic polymorphisms gives rise to considerable …

Aims Interindividual differences in the pharmacokinetics of venlafaxine, a new
antidepressant, were shown during early clinical trials in Japan. Venlafaxine is metabolized …

Venlafaxine (brand name Effexor) is an antidepressant used in the treatment of major
depressive disorder, anxiety, and panic disorders. Venlafaxine belongs to the drug class of …